Stockreport

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent [Read more]